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Abstract
Background: Intravenous iron is widely used to control anemia in dialysis patients and limits costs related to
erythropoiesis-stimulating agents (ESA). Current guidelines do not clearly set upper limits for serum ferritin
(SF) and transferrin saturation (TSAT). International surveys such as the Dialysis Outcomes and Practice Patterns
Study (DOPPS) showed that this lack of upper limits potentially led nephrologists to prescribe iron infusions
even for patients with a high SF. Recent publications have suggested a risk of short- and long-term adverse
effects related to iron overload. We conducted a proof of concept study to assess the impact of reducing
intravenous iron administration.
Methods: In a prospective 8-month study conducted in a hospital dialysis unit, we assessed the impact of a strategy
designed to reduce iron infusions. Instead of the usual strategy targeting 30–50% TSAT irrespective of SF, intravenous
iron was administered if and only if TSAT was below 20% and SF below 200 μg/L. Routine practices for ESA remained
unchanged: hemoglobin target 10–12 g/dL; ESA delivered monthly and dose corrected by 25% as necessary; ESA
discontinued temporarily if hemoglobin >13 g/dL; methoxy polyethylene glycol-epoetin beta generally used. Tests
were ordered monthly to monitor hemoglobin. Intravenous iron was administered weekly and ESA monthly. Baseline
and 6-month TSAT, SF and hemoglobin levels were compared.
Results: Six-month data were available for 45 patients (31 M/14 F; 67.6 ± 14.0 y; 53.9 ± 85.7 months on dialysis). Patients
experienced the following comorbidities: ischemic heart disease (n = 29, 44%), diabetes mellitus (n = 14; 31%), malignant
disease (n = 11; 24%), transplantation (n = 11; 24%) and severe heart failure (n = 6; 13%). The mean weekly dose of iron
declined from 77.8 ± 87.6 to 24.4 ± 52.9 mg per patient (p= 0.0003). SF decreased from 947.7 ± 1056.4 to 570.7 ± 424.
4 μg/L (p= 0.0001), and TSAT from 41.5 ± 22.4 to 32.6 ± 13.7% (p = 0.01). Hemoglobin levels remained stable (11.13 ± 1.05
vs. 11.00 ± 1.16 g/dL, p = 0.54) as did ESA dose (126.4 ± 91.9 vs. 108.2 ± 112.7 μg/28 days, p = 0.07).
Conclusions: Our study suggests that a regular hemoglobin level can be maintained using regular ESA doses combined
with intravenous iron doses adapted to TSAT and SF thresholds lower than those used in routine practice. This strategy
reduces the risk of iron overload.
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Background
Although optimal therapeutic management of anemia in
hemodialysis patients is still debated, there is a consen-
sus on avoiding blood transfusions. Treatment of anemia
was demonstrated to be correlated with an improvement
in the quality of life and a reduction in morbi-mortality
[1–4]. Some studies, however, highlighted a potential for
harm from an overtreatment of anemia by showing that
too high target hemoglobin levels were associated with
an increased cardiovascular risk [5, 6].
Recommendations for the use of iron and erythropoiesis-
stimulating agent (ESA) infusions are not unanimous
[7–15]. The choice of biomarkers to monitor iron supple-
mentation, as well as the target levels remains a matter for
debate (Table 1). The use of intravenous (IV) iron in dialysis
patient has increased substantially since the early 2000s
[16–19]. This increase was based on results from clinical
studies showing a greater ESAs responsiveness in patients
receiving iron supplementation [20–23]. The financial
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criterion has remained, up until recently, a determin-
ant for IV iron prescribing as shown by escalating
trends in its utilization following changes in financial
contribution to the treatment of anemia decided by
the American Health System in the early 2010s [17].
In addition to its effectiveness for treating anemia,
other benefits of IV iron supplementation, particularly
cardiovascular, may have contributed to the rise of its
prescribing [24–26]. In this context, the lack of an
agreement about the level of an upper limit for serum
ferritin in international guidelines may be partly re-
sponsible for the acceptance of some very high values
for serum ferritin by nephrologists.
Since 2000, several studies have raised concerns about a
long-term iron supplementation with supra-physiological
doses in renal insufficiency. Thus mortality rate was shown
to be correlated with iron dose in the Dialysis Outcomes
and Practice Patterns Study (DOPPS) [27]. Several pro-
spective studies demonstrated potential adverse effects due
to prolonged use of high dose IV iron [4, 28–32]. Liver iron
overload was demonstrated in almost all hemodialysis
patients receiving IV iron using magnetic resonance
imaging techniques [33, 34]. In addition, several cases of
anaphylaxis associated with IV iron infusions were re-
ported [35, 36]. Although it is very difficult to ascertain the
frequency of these severe reactions associated with IV iron,
it was estimated at one reaction for every five million doses
from US data [35]. In addition, three deaths per year were
ascribed to intravenous iron infusions in US death certifi-
cate data [35].
As a result, the use of IV iron was regulated by the French
and European Health Authorities [37, 38]. Taking into
account of these recent data, experts have become more
cautious about iron supplementation in dialysis [39–41].
In this context, we expressed a desire to change our
IV iron supplementation practices by switching from
widely prescribing that was presumed to be safe until
now to responsible prescribing. Thus we have restricted
IV iron supplementation to patients with both serum
ferritin levels under 200 μg/L and transferrin saturation
(TSAT) under 20%. The change in our IV iron supple-
mentation practices for the management of iron defi-
ciency in hemodialysis patients has been systematically
implemented in our dialysis unit since February 2014.
Methods
Study design
We conducted a prospective 8-month study to assess
the efficacy and the safety of this approach that was
more restrictive in iron supplementation for the man-
agement of anemia among all patients undergoing dialy-
sis in our hospital dialysis unit.
Enrolled patients were all adults who had been on
dialysis for at least 3 months in our unit. During dialysis
sessions, they were given anticoagulant as an initial
single bolus of enoxaparine or a continuous infusion of
heparin sodium. Routine practices for ESA remained
unchanged: hemoglobin target levels were 10–12 g/dL;
ESA was delivered monthly and its dose could be
adjusted by 25% as necessary; ESA was discontinued
temporarily if hemoglobin was above 13 g/dL; methoxy
polyethylene glycol-epoetin beta was mainly used.
Biochemical parameters for iron status and for the as-
sessment of anemia had been followed in all patients
Table 1 Clinical practice guidelines for anemia management in chronic kidney disease according to transferring saturation, serum
ferritin and upper limit of serum ferritin for iron supplementation
Guidelines TSAT(%) Serum ferritin (μg/L) Upper limit of serum ferritin (μg/L)
KDOQI 2006 [16] <20 <100 500
CSN 2008 [18] HD <20 <200 None
PD/ND <20 <100 None
JSDT 2008 [11] <20 <100 500
ERBP 2009 [17] <20 <100 500
KDIGO 2012 [7] <30 <500 500 (or TSAT > 30%)
CSN 2012 [10] <30 <500 None
ERBP 2013 [8] No ESA/no anemia <20 <100 500
No ESA/anemia/ND <25 <200 500
No ESA/anemia/HD or PD <25 <300 500
ESA/anemia/on dialysis <30 <300 500
KDOQI 2013 [9] <30 <500 None
NICE 2015 [12] <20 <100 800
KDOQI Kidney Disease Outcomes Quality Initiative, CSN Canadian Society of Nephrology, JSDT Japanese Society of Dialysis Therapy, KDIGO Kidney Disease
Improving Global Outcomes, ERBP European Renal Best Practice, NICE National Institute for Health and Care Excellence, HD on hemodialysis, PD peritoneal dialysis,
ND not on dialysis, ESA erythropoiesis-stimulating agent, TSAT transferrin saturation
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undergoing dialysis in our unit between February and
September, 2014.
Data collection
At the beginning of the follow-up, we collected medical
history, treatment and the main biochemical parameters
for all patients. We checked comorbidities associated
with chronic kidney disease (CKD), such as diabetes,
ischemic cardiopathy, cancer, malignant blood disease,
and digestive disease, as well as treatment, particularly
anticoagulant and antiplatelet agents.
Regarding dialysis sessions, we reported the following
parameters: treatment options for renal replacement ther-
apy, such as hemodialysis or hemodiafiltration, weekly
duration of dialysis sessions, and ESA dose.
The following biochemical parameters were assessed
every 28 days: hemoglobin, TSAT, serum ferritin, serum
calcium, serum phosphorus, serum β2-microglobuline,
serum albumin and C-reactive protein (CRP). Parathy-
roid hormone (PTH) level was assessed within the first
weeks after the beginning of the study and at the end of
the follow-up period. The following patient outcomes
had been reported throughout the follow-up: death,
transplantation, presence in our dialysis unit after a 6-
month follow-up and transfer to another dialysis unit, as
well as hospitalizations and reasons of admissions.
Regimens of IV iron supplementation
At the beginning of the study, the target dose-regimen
for IV iron supplementation aimed to maintain TSAT
between 30 and 50%, irrespective of serum ferritin
levels, in ESA-treated patients in order to avoid iron
deficiency anemia. In ESA-naive patients, IV iron
supplementation was given in those with hemoglobin
level under 12 g/dL or iron deficiency (serum ferritin
< 200 μg/L and TSAT < 20%).
Our new therapeutic strategy for iron deficiency ther-
apy aimed to prescribe IV iron supplementation only in
anemic patients with TSAT <20% and serum ferritin
< 200 μg/L, simultaneously. The weekly iron dose was 100
or 200 mg in patients requiring iron supplementation.
In our unit, iron is administered intravenously as a
weekly single dose during the midweek dialysis session
in patients on hemodialysis three times per week. Our
source of iron is ferric hydroxide sucrose complex.
Assessment criteria
The main assessment criterion was the change in
hemoglobin levels after adaptation of IV iron therapy in
patients with a 6-month follow-up in our unit.
The secondary criteria were the change in TSAT,
serum ferritin levels and ESA dose after a 6-month
follow-up period.
Statistical analysis
Comorbidities in patients at inclusion, as well as charac-
teristics of treatment and dialysis sessions are expressed
in % of patients. Biochemical parameters, iron doses and
ESA doses are described by mean and standard
deviation. Student’s t-test and McNemar’s test were used
to compare change of biochemical parameters and of
IV iron prescription during the study, respectively.
Results
Among the 55 patients undergoing dialysis in our unit at
the beginning of the study, 45 had been followed up
throughout the study as shown in Fig. 1.
Patient characteristics
Sample characteristics are detailed in Table 2. Our popu-
lation study consisted mainly of men (68.9%). The mean
age was 67.6 ± 14.0 years. The mean duration of renal
replacement therapy was 53.9 ± 85.7 months. The most
common cause of end-stage renal failure was hyperten-
sive nephropathy. Ischemic heart disease and diabetes
were the most concomitant pathologies. The majority of
patients were given antiplatelet agents.
Anticoagulation with low molecular weight heparin
(LMWH) during dialysis sessions was used in all pa-
tients. The mean duration of dialysis session was 13.1 ±
Fig. 1 Flow diagram of the study
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1.7 h per week. Patients were undergoing hemodialysis
(68.9%) and hemodiafiltration (31.1%).
Patients’ outcomes
Patients were followed up during 22.5 patient-years.
Reported reasons for lost to follow-up (transplant-
ation, death, center change or unavailable data) are de-
tailed in Fig. 1. The causes of deaths were attributed to
cardiovascular diseases (N = 3) and infection (N = 1).
Temporary absences from our unit were due to transient
dialysis in other centers for medical reasons or holidays.
A total of 27 hospital admissions have been recorded
during the follow-up, i.e. a hospitalization rate of 1.2
patient-years. Infections were responsible for one out of
four admissions.
Biochemical parameters
Hemoglobin levels remained stable throughout the
follow-up (p = 0.54) (Fig. 2a). An expected significant
decrease, by contrast, was observed for biochemical
markers of iron status, such as serum ferritin (p =
0.0001) and TSAT (p = 0.01) (Fig. 2b and c). During the
same period, the number of patients with iron deficiency
anemia remained stable; the number of patients with
TSAT values under 20% decreased from 8 to 7; the num-
ber of patients experiencing serum ferritin levels under
200 μg/L quadrupled, without any patient with serum
ferritin levels under 100 μg/L. PTH and CRP levels
remained stable throughout the follow-up. β2 microglo-
buline significantly decreased (p = 0.00001) and serum
albumin levels significantly increased (p = 0.0002), as
shown in Table 3.
Management of anemia
At the beginning of the study, patients were given a
mean weekly iron dose of 77.8 ± 87.6 mg - i.e. IV iron
infusion of 310 mg per month. Among the 45 patients
with a follow-up, 25 patients were given IV iron infusion
during dialysis sessions; the mean weekly iron dose of
iron was 140.0 ± 70.1 mg – i.e. IV iron infusion of
560 mg per month.
After a 6-month period, the mean weekly iron dose
was significantly reduced to 24.4 ± 52.9 mg (p = 0.0003)
– i.e. IV iron infusion of 97.6 mg per month (Fig. 3).
Only nine patients out of the 45 patients were treated
with a mean weekly iron dose of 122.2 ± 44.1 mg – i.e.
IV iron infusion of 488 mg per month. In addition, the
number of patients receiving IV iron infusion was
significantly reduced from 50 to 20% (p = 0.001).
At the beginning of the follow-up the mean ESA dose
was 126.4 ± 91.9 μg/patient/28 days (N = 45); 42 patients
were treated and were given a mean ESA dose of 135.4
± 88.4 μg/patient/28 days, while 3 patients did not re-
ceive ESA (Fig. 2d). At the end of the follow-up period,
the mean ESA dose was 108.2 ± 112.7 μg/patient/28 days
(N = 45); 36 patients were treated and were given a mean
ESA dose of 135.2 ± 110.5 μg/patient/28 days, while nine
patients did not receive ESA. ESA dose remained stable
during the follow-up (p = 0.07). All treatments of anemia
are detailed in Table 3.
Discussion
The present study highlighted that lower targets for
serum ferritin and TSAT enabled a reduction of iron
supplementation without lowering hemoglobin levels or
increasing ESA dose. The targets for serum ferritin and
TSAT we used to adapt treatment were in accordance
with the current international guidelines for the manage-
ment of anemia [7, 8]. Biomarkers and targets recom-
mended for anemia management have been regularly




Age (years) 67,58 ± 14,02
History of chronic kidney disease, N (%)
Hypertensive nephropathy 21 (46.7%)







Malignant disease 11 (24.4%)
Infection 11 (24.4%)
Hemorrhage 12 (26.7%)
Heart disease 29 (64.4%)
Ischemic heart disease 20 (44.4%)
Heart failure 6 (13.3%)
Previous time of dialysis (months) 53,97 ± 86,26
Type of dialysis, n (%)
Hemodialysis 32 (71%)
Hemodiafiltration 13 (29%)
Vascular access, N (%)
Arteriovenous fistula 37 (82.2%)
Arteriovenous graft 3 (6.7%)
Venous catheter 5 (11.1%)
Treatment, N (%)
Anticoagulants 7 (15.6%)
Antiplatelet agents 32 (71.1%)
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Fig. 2 Box-and-whisker plots of change in biochemical indicators of iron status and ESA doses during the follow-up period. a Box-and-whisker plots of
change in hemoglobin levels during the follow-up period. Limits of boxes are 1st quartile (lower limit) and 3rd quartile (upper limit), with + and □ being the
mean and median values, respectively. Ends of whiskers indicate 1st decile (lower end) and 9th decile (upper end) (p= 0.54). b Box-and-whisker plots of
change in TSAT during the follow-up. Limits of boxes are 1st quartile (lower limit) and 3rd quartile (upper limit), with + and □ being the mean and median
values, respectively. Ends of whiskers indicate 1st decile (lower end) and 9th decile (upper end) (p= 0.01). c Box-and-whisker plots of change in serum ferritin
during the follow-up. Limits of boxes are 1st quartile (lower limit) and 3rd quartile (upper limit), with + and □ being the mean and median values, respectively.
Ends of whiskers indicate 1st decile (lower end) and 9th decile (upper end) (p= 0.0001). d Box-and-whisker plots of change in prescribed ESA doses during
the follow-up. Limits of boxes are 1st quartile (lower limit) and 3rd quartile (upper limit), with + and □ being the mean and median values, respectively. Ends
of whiskers indicate 1st decile (lower end) and 9th decile (upper end) (p= 0.07)
Table 3 Comparisons of biochemical parameters and treatment for anemia during the 6-month follow-up
At inclusion (M0) At month 3 At month 6 P
Biochemical parameters
Hemoglobin (g/dL) 11.13 ± 1.05 11.30 ± 1.09 11.00 ± 1.16 0.54
TSAT (%) 41.47 ± 22.37 29.27 ± 10.88 32.58 ± 13.63 0.01
Serum ferritin (μg/L) 947.71 ± 1056.42 672.93 ± 490.16 570.73 ± 424.41 0.0001
Parathyroid hormone (pg/mL) 188.03 ± 154.67 ND 212.73 ± 176.85 0.27
β2-microglobuline (mg/L) 25.88 ± 7.77 22.96 ± 5.57 21.80 ± 6.53 0.00001
C-reactive protein (mg/L) 14.59 ± 27.10 9.04 ± 10.14 11.81 ± 30.60 0.64
Serum albumin (g/L) 35.07 ± 4.52 37.34 ± 2.99 40.02 ± 4.58 0.0002
Treatment
ESA (μg/28 days) 126.4 ± 91.9 109.63 ± 101.03 108.20 ± 112.70 0.07
Iron supplementation (mg/week) 77.78 ± 87.62 15.56 ± 42.40 24.44 ± 52.90 0.0003
ESA erythropoiesis-stimulating agent
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revised by Healthcare Institutions, but are still discussed.
Although serum ferritine level and TSAT are traditional
biomarkers of iron storage in patients with anemia, there
are some concerns regarding their relevance [42, 43].
There are alternative indicators of iron metabolism, such
as percentage of hypochromic red blood cells, reticulo-
cyte hemoglobin content, soluble transferrin receptor
and serum hepcidin. As these serum biomarkers are not
routinely measured, we did not assess them in our study.
However, it could be interesting to monitor them within
the framework of a strategy for lowering IV iron
supplementation.
Efficacy of different routes of administration in iron
deficiency therapy was compared, and IV iron infusions
seemed to be more efficient than oral iron in CKD pa-
tients, in both non dialysis [44, 45] and dialysis patients
[22, 46]. However, this should be weighed against some
potential complications associated with IV iron infu-
sions. The risk of hypersensitivity reactions during IV
iron infusions have led the Health Authorities in Europe
and in France to recommend new precautions for IV
iron supplementation [37, 38]. In particular, IV iron
medicines should only be administered in medical insti-
tutions with resuscitation facilities in France. In the light
of these data, the current guidelines from the Health
Societies and Pharmaceutical Manufacturers recommend
that oral iron therapy may still be used as the first
option in iron deficiency therapy, especially in non-
dialysis CKD patients, and IV iron infusion should only
be considered in both patients experiencing intoler-
ance and failure to respond to oral iron [7, 8]. Our
approach to lower IV iron supplementation should
permit to limit the risk of anaphylaxis by reducing
the frequency of infusions.
Several IV iron-containing medicines are currently
available [40], and each formulation has its own usage
instructions. In our unit, an iron saccharose complex is
given intravenously at the weekly dose of 100 or 200 mg
as a single infusion during the midweek dialysis sessions.
Clinical practices for the use of IV iron supplementation
in dialysis differ in terms of drugs, dosing frequency, and
amount, but at our knowledge, there is no register for all
these practices. Results from a retrospective study
comparing maintenance infusions of low iron doses to
bolus administration of higher and less frequent doses
suggested a correlation between the practice of bolus
dosing and the risk of infection [30, 47]. More recently,
a study was performed to focus on the highest iron
amount infused per month without liver iron overload
and suggested that the threshold dose should be 250 mg
monthly [48].
In our study, reduction in iron amount was more im-
portant in the first months of the follow-up (Fig. 2), illus-
trating a progressive utilization of iron stores in our
patients. However, iron amount was significantly different
at the beginning versus the end of the study and achieved
a stable amount fivefold lower than the previous one used
before the implementation of the new approach. The
utilization of iron store observed in our study needs to be
viewed against the absence of incident dialysis patients
who are more likely to experience iron deficiency.
In addition, hemoglobin levels remained in the recom-
mended therapeutic window. We have maintained the
biochemical monitoring of our dialysis patients and did
not show any compensatory increase of iron amount
and ESA dose after a 1-year period.
Our study has some limitations related to the size
of our dialysis unit. Our findings need therefore to be
confirmed in larger studies including a comparison
with a control group. However, our study is the first
observational study suggesting that an approach to
lower IV iron supplementation is applicable in dialysis
settings without increasing ESA dosing and lowering
hemoglobin levels.
Fig. 3 Iron supplementation during the follow-up period
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Conclusion
Iron plays a central role in the management of anemia
of hemodialysis patients and may improve ESA respon-
siveness. It is widely used nowadays in daily practice in
dialysis units, even when ferritin and TSAT levels are
high. As IV iron supplementation can induce severe
adverse effects, challenges faced by prescribing physi-
cians are especially to achieve the lowest effective dose.
Our study suggests that a strategy designed to lower IV
iron supplementation can be applied in a wide range of
dialysis units without lowering hemoglobin level or
increasing ESA dosing in hemodialysis patients. Further
prospective larger studies with a control group are
needed to validate this approach in hemodialysis pa-
tients. Regarding current clinical practices, a moderate
IV iron supplementation seems realistic in everyday clin-
ical practice.
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